EPS for Protalix BioTherapeutics, Inc. (PLX) Expected At $-0.06

February 20, 2018 - By Vivian Park

 EPS for Protalix BioTherapeutics, Inc. (PLX) Expected At $ 0.06

Analysts expect Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) to report $-0.06 EPS on March, 15.After having $-0.09 EPS previously, Protalix BioTherapeutics, Inc.’s analysts see -33.33 % EPS growth. The stock increased 0.15% or $0.001 during the last trading session, reaching $0.655. About 331,219 shares traded. Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) has declined 0.01% since February 20, 2017 and is downtrending. It has underperformed by 16.71% the S&P500.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company has market cap of $94.32 million. The firm offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. It currently has negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis.

More notable recent Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) news were published by: Globenewswire.com which released: “Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II …” on February 15, 2018, also Seekingalpha.com with their article: “Protalix BioTherapeutics’ (PLX) CEO Moshe Manor on Q2 2017 Results – Earnings …” published on August 09, 2017, Valuewalk.com published: “Protalix BioTherapeutics, Inc. (PLX) and Lands’ End, Inc. (LE) Activist Update” on January 25, 2018. More interesting news about Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) were released by: Seekingalpha.com and their article: “Protalix BioTherapeutics: An Update On The Fabry Disease Franchise” published on November 23, 2017 as well as Globenewswire.com‘s news article titled: “Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global …” with publication date: September 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.